BioSpace News Archive

TOMI Environmental Solutions, Inc.®, is a global company specializing in disinfection and decontamination, utilizing its premier Binary Ionization Technology platform through its SteraMist products - a hydrogen peroxide-based mist and fog composed of ionized Hydrogen Peroxide.

STI-6991 is an I-CellTM COVID-19 cellular vaccine made of replication-deficient human erythroleukemia K562 cells expressing membrane-bound S1 protein of the SARS-CoV-2 virus

The total costs for all hospitalized COVID-19 patients may range from a low of $362 billion in charges and $139 billion in estimated in-network amounts to a high of $1.449 trillion in charges and $558 billion in estimated in-network amounts, depending on the incidence rate and severity of the infection in the US population.

PINGMD announced that it would make its HIPAA-secure communication and video TeleHealth and TeleMedicine App, PINGMD, available FREE for medical professionals and their patients for the duration of COVID-19 pandemic.

Cyber Power Systems, Inc., a leader in power protection and management products, has launched two new medical-grade products, expanding its product line for the healthcare industry.

Recursion, a digital biology company industrializing drug discovery, today announced the appointment of Michael Secora, Ph.D., as its Chief Financial Officer, focused primarily on the company’s fundraising and strategic finance events and leveraging his decade-plus of experience investing at the intersection of biology and technology.

The National Kidney Foundation (NKF) showcased this week a new study for a drug treatment to address metabolic acidosis in patients with kidney disease which significantly improved how patients felt and functioned.

PharmaJet®, the maker of innovative, needle-free injection technology, today announced that Dr. Marie Mazur, has been appointed to its Board of Directors.

Today, the National Kidney Foundation (NKF) showcased a global study designed to understand the experimental immunosuppressant drug Voclosporin as a treatment for patients with lupus kidney disease.

To facilitate inpatient capacity across the health care system during the COVID-19 state of emergency, Blue Cross Blue Shield of Massachusetts has removed prior authorization requirements and moved to a notification-only requirement for inpatient levels of care including Acute, Long Term Acute, Acute and Subacute Rehabilitation, and Skilled Nursing Facility admissions.